No open-market selling at ProQR Therapeutics N.V. in the past year, which is unusual. Instead two the people running the company bought about $1.3 million worth of PRQR.
de Boer Daniel Anton (CEO) made the biggest buy, worth around $354,000. That includes C-suite money, which tends to get the most attention.
Quarter by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | de Boer Daniel Anton | CEO | Buy | 200,000 | $1.77 | $354K | SEC |
| Jul 21, 2026 | Filius Bart | Director | Buy | 150,000 | $1.72 | $258K | SEC |
| Jul 13, 2026 | de Boer Daniel Anton | CEO | Buy | 150,000 | $1.74 | $261K | SEC |
| Jul 8, 2026 | de Boer Daniel Anton | CEO | Buy | 150,000 | $1.59 | $238K | SEC |
| Jun 30, 2026 | Filius Bart | Director | Buy | 150,000 | $1.54 | $231K | SEC |
In the last 12 months ProQR Therapeutics N.V. insiders made open-market purchases worth about $1.3 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in PRQR was filed on 2026-08-03.
No congressional trades in PRQR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).